Intellectia LogoIntellectia
Product
Resources
Markets
News
Partner Program
Pricing
Log inTry for Free
Intellectia Logo
Log in
Intellectia Logo

Product

Features
Financial AI Agent
Stock Technical Analysis
Stock Monitor
Hedge Fund Tracker
AI Screener
Trading Strategies
AI Stock Picker
Swing Trading
Quant AI
Stock Chart Patterns
Daytrading Center
AI Earnings Prediction
Whales Auto Tracker
Backtesting Playground

Resources

Learn
Blog
Earnings
Tutorial
Help Center
Company
About Us
Contact
Press
Reward Program
Partner Program
Tools
Dividend Calculator
Dividend Yield Calculator
Options Profit Calculator
Compare
TradingView
SeekingAlpha

Markets

Trending Stocks
Hot Crypto
Trending News
All Stocks

News

Trading News
Overview
Top News
Daily Market Brief
Earnings
Latest
Newswire
Stock News
Crypto News
Monitor News
Partner ProgramPricing
Start for Free
  1. Home
    2. >
  2. Stock
    3. >
  3. DARE
stocks logo

DARE

-
collectAdd to Watchlistadvanced chartAdvanced Chart
$
0.000
0(0.000%)1D
collectadvanced chart
    Overview
    Forecast
    Valuation
    Earnings
High
--
Open
--
VWAP
--
Vol
--
Mkt Cap
--
Low
--
Amount
--
EV/EBITDA(TTM)
--
Total Shares
--
EV
--
EV/OCF(TTM)
--
P/S(TTM)
--
Financial AI Agent
Financial AI Agent

Market Estimates

Earnings Estimates
Earnings Estimates
Revenue
YoY Chg
EPS
YoYChg
FY2025Q4
FY2026Q1
FY2026Q2
765.00K
-1301.89%
-0.432
-33.46%
1.58M
+6093.47%
-0.360
-28%
2.38M
-11344.69%
-0.365
-18.89%
Estimates Revision
The market is revising No Change the revenue expectations for Daré Bioscience, Inc. (DARE) for FY2025, with the revenue forecasts being adjusted by 0% over the past three months. During the same period, the stock price has changed by -16.74%.
Revenue Estimates for FY2025
No Change
down Image
0.00%
In Past 3 Month
EPS Estimates for FY2025
No Change
down Image
0.00%
In Past 3 Month
Stock Price
Go Down
down Image
-16.74%
In Past 3 Month
Wall Street analysts forecast DARE stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for DARE is 10.00 USD with a low forecast of 8.00 USD and a high forecast of 12.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
2 Analyst Rating
Wall Street analysts forecast DARE stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for DARE is 10.00 USD with a low forecast of 8.00 USD and a high forecast of 12.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
2 Buy
0 Hold
0 Sell
Moderate Buy
Current: 1.790
sliders
Low
8.00
Averages
10.00
High
12.00
Current: 1.790
sliders
Low
8.00
Averages
10.00
High
12.00
Maxim
Jason McCarthy
Hold
to
Buy
upgrade
$8
2025-09-04
Reason
Maxim
Jason McCarthy
Price Target
$8
2025-09-04
upgrade
Hold
to
Buy
Reason
Maxim analyst Jason McCarthy upgraded Dare Bioscience to Buy from Hold with an $8 price target.
HC Wainwright & Co.
Douglas Tsao
Strong Buy
Reiterates
$12
2025-04-01
Reason
HC Wainwright & Co.
Douglas Tsao
Price Target
$12
2025-04-01
Reiterates
Strong Buy
Reason
HC Wainwright & Co.
Douglas Tsao
Strong Buy
Reiterates
$12
2024-12-17
Reason
HC Wainwright & Co.
Douglas Tsao
Price Target
$12
2024-12-17
Reiterates
Strong Buy
Reason
See All Ratings

Valuation Metrics

The current forward P/E ratio for Dare Bioscience Inc (DARE.O) is -2.60, compared to its 5-year average forward P/E of -3.00. For a more detailed relative valuation and DCF analysis to assess Dare Bioscience Inc 's fair value, click here.
  • Forward PE
  • Forward EV/EBITDA
  • Forward PS

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average PE
-3.00
Current PE
-2.60
Overvalued PE
-0.76
Undervalued PE
-5.24

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average EV/EBITDA
0.00
Current EV/EBITDA
0.00
Overvalued EV/EBITDA
0.00
Undervalued EV/EBITDA
0.00

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average PS
16.15
Current PS
0.00
Overvalued PS
34.20
Undervalued PS
-1.89
AI Stock Picker
AI Stock Picker

Financials

Annual
Quarterly
N/A
Total Revenue
N/A
Operating Profit
N/A
Net Income after Tax
N/A
EPS - Diluted
N/A
Free Cash Flow
N/A
Gross Profit Margin - %
N/A
FCF Margin - %
N/A
Net Margin - %

Trading Trends

  • Insider
  • Hedge Fund
  • Congress Trading
Insider
Insiders are Neutral. There are no significant trading trends over the last month.
Sold
Bought
Hedge Fund
Hedge Funds are Neutral. There are no significant trading trends over the last quarter.
Sold
Bought
Congress Trading
Congress are Neutral. There are no significant trading trends over the last month.
Sold
Bought
Insider
Insiders are Neutral. There are no significant trading trends over the last month.
Sold
Bought
Intellectia AI SwingMax
Intellectia AI SwingMax

DARE News & Events

Events Timeline

(ET)
2025-12-01
08:20:00
Dare Bioscience Regains Ovaprene Rights from Bayer, Effective February 2026
select
2025-11-24 (ET)
2025-11-24
08:29:08
Dare Bioscience Secures $3.6 Million in Extra Grant Funding
select
2025-11-13 (ET)
2025-11-13
16:11:51
Dare Bioscience Announces Q3 Earnings Per Share of 28 Cents, Below Consensus Estimate of 38 Cents
select
Sign Up For More Events
Sign Up For More Events

News

[object Object]
Preview
3.5
12-01Newsfilter
Daré Bioscience Regains Ovaprene® Rights, Advancing Women's Health Innovation
  • Consolidation of Rights: Daré Bioscience announced the return of commercialization rights for Ovaprene®, enhancing the company's strategic position in women's health, effective February 2026, marking full control over this critical asset.
  • Clinical Trial Progress: The Phase 3 clinical trial for Ovaprene is underway, supported by non-dilutive funding, with positive interim data indicating favorable safety and tolerability, positioning it to potentially become the first FDA-approved hormone-free monthly intravaginal contraceptive.
  • Market Potential: As an innovative non-hormonal contraceptive option, Ovaprene addresses a significant gap in women's health, expected to attract broad strategic interest from pharmaceutical and consumer health organizations, further driving company growth.
  • Increased Strategic Flexibility: By consolidating global commercialization rights, Daré can explore the most attractive commercial and access pathways, including partnerships and non-traditional commercialization models, maximizing long-term economic benefits.
[object Object]
Preview
9.5
11-14NASDAQ.COM
Daré Bioscience (DARE) Third Quarter 2025 Earnings Call Transcript
  • Author's Perspective: The views and opinions presented are solely those of the author.
  • No Official Endorsement: The content does not necessarily reflect the views of Nasdaq, Inc.
[object Object]
Preview
7.5
11-03Newsfilter
Daré Bioscience Set to Receive Up to $300,000 for Global Assessment of Contraceptive Innovation Capabilities

  • Funding Announcement: Daré Bioscience has secured a contract with the Gates Foundation for up to $300,000 to conduct a strategic review of organizations involved in contraceptive product development.

  • Objective of the Initiative: The project aims to identify and evaluate both for-profit and non-profit organizations globally that have expertise in formulation development, clinical trial design, and regulatory support for contraceptive products.

  • Company Mission: Daré Bioscience focuses on addressing gaps in women's health through rigorous scientific research and aims to accelerate the development of innovative contraceptive and reproductive health solutions.

  • Leadership Recognition: The leadership of Daré Bioscience has received accolades for their contributions to women's health innovation, highlighting the company's commitment to advancing credible, science-based solutions.

Sign Up For More News

People Also Watch

FAQ

arrow icon

What is Dare Bioscience Inc (DARE) stock price today?

The current price of DARE is 1.79 USD — it has increased 2.58 % in the last trading day.

arrow icon

What is Dare Bioscience Inc (DARE)'s business?

Dare Bioscience, Inc. is a biopharmaceutical company. The Company's programs target unmet needs in women's health, primarily in the areas of contraception, sexual health, pelvic pain, fertility, infectious disease, vaginal health and menopause. Its product includes XACIATO (clindamycin phosphate) vaginal gel 2%. XACIATO is a single-dose prescription medication for the treatment of bacterial vaginosis in females 12 years of age and older. Its other product candidates include Ovaprene, Sildenafil Cream, and DARE-HRT1. Ovaprene is an investigational, hormone-free, monthly intravaginal contraceptive. Sildenafil Cream is a novel cream formulation of sildenafil for the treatment of female sexual arousal disorder; and DARE-HRT1 is an intravaginal ring designed to deliver a combination of menopausal hormone therapy, bio-identical 17b-estradiol and progesterone together, continuously over a 28-day period for the treatment of moderate to severe vasomotor symptoms, also known as hot flashes.

arrow icon

What is the price predicton of DARE Stock?

Wall Street analysts forecast DARE stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for DARE is 10.00 USD with a low forecast of 8.00 USD and a high forecast of 12.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

arrow icon

What is Dare Bioscience Inc (DARE)'s revenue for the last quarter?

Dare Bioscience Inc revenue for the last quarter amounts to 2.26K USD, decreased -94.57 % YoY.

arrow icon

What is Dare Bioscience Inc (DARE)'s earnings per share (EPS) for the last quarter?

Dare Bioscience Inc. EPS for the last quarter amounts to -0.28 USD, decreased -49.09 % YoY.

arrow icon

What changes have occurred in the market's expectations for Dare Bioscience Inc (DARE)'s fundamentals?

The market is revising No Change the revenue expectations for Daré Bioscience, Inc. (DARE) for FY2025, with the revenue forecasts being adjusted by 0% over the past three months. During the same period, the stock price has changed by -16.74%.
arrow icon

How many employees does Dare Bioscience Inc (DARE). have?

Dare Bioscience Inc (DARE) has 21 emplpoyees as of December 05 2025.

arrow icon

What is Dare Bioscience Inc (DARE) market cap?

Today DARE has the market capitalization of 25.72M USD.

Intellectia LogoIntellectiaIntellectia LogoIntellectia

Redefine Your Investment Decisions

TwitterTwitterYoutubeYoutubeQuoraQuoraDiscordDiscordLinkedinLinkedinTelegramTelegram
AppStoreGooglePlay

Copyright © 2025 Intellectia.AI. All Rights Reserved.

pci certified logo
Company
HomeContactAbout UsNews Release
Compare
TradingViewSeeking Alpha
Features
Financial AI AgentStock Technical AnalysisStock MonitorHedge Fund TrackerAI ScreenerDaytrading Center
Strategies
AI Stock PickerSwing TradingStock Chart PatternsEarnings TradingDaytrading CenterAI Earnings PredictionQuant AIWhales Auto TrackerBacktesting Playground
Free Tools
Dividend CalculatorDividend Yield CalculatorOptions Profit Calculator
Resource
BlogTutorialEarningsTrending StocksCrypto MarketPartner ProgramTerms of UsePrivacy PolicySecuritySitemap
Start for Free